Inhibikase Therapeutics, Inc. · NASDAQ:IKT
Sands Capital Life Sciences Pulse Fund II, L.P. reported a 14.70% stake in Inhibikase Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2025 · Filed Aug 13, 2025
Sands Capital Life Sciences Pulse Fund II, L.P. reported a 14.70% stake in Inhibikase Therapeutics, Inc., 10,950,000 shares, as a passive investor on Jun 30, 2025. Filed Aug 13, 2025 (Schedule 13G/A).
- Stake
- 14.70%
- Shares
- 10,950,000
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 14.70% | 10,950,000 |
| Sands Capital Alternatives, LLC | 14.70% | 10,950,000 |
| SANDS FRANK M. | 14.70% | 10,950,000 |
Source
Related
- Inhibikase Therapeutics, Inc.
- Sands Capital Life Sciences Pulse Fund II, L.P.
- Inhibikase Therapeutics, Inc. shareholders
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Feb 13, 2026
- Schedule 13G/A · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026
- Form 4 · Berman Dennis N · Jul 31, 2026
- Form 4 · RA Capital Healthcare Fund LP · Jul 31, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Jul 31, 2026